USFDA Gives Torrent Pharma’s Indrad Facility A Thumbs Up With VAI Classification

Torrent Pharmaceuticals has announced that the US Food and Drug Administration (USFDA) has issued an Establishment Inspection Report (EIR) for its Indrad facility in Gujarat, following an inspection conducted from June 3 to June 12, 2024. The facility received a "Voluntary Action Indicated" (VAI) classification, indicating that while some observations were made, the company can continue its operations.

This announcement follows Torrent Pharma's earlier notification about the start of the inspection. With the issuance of the EIR, the USFDA has officially closed the inspection process. The VAI status allows Torrent to maintain its manufacturing activities while working on the noted observations. This outcome is a significant achievement for Torrent Pharmaceuticals, as it reinforces the company’s standing in highly regulated markets like the United States, where adherence to strict regulatory standards is vital for gaining product approvals. 

Torrent Pharma remains focused on maintaining top-tier manufacturing standards and addressing any areas for improvement to enhance its operational performance. The successful closure of this inspection is likely to boost investor confidence and open doors for new growth opportunities in the pharmaceutical industry.